Jun 9, 2025 09:00AM Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025

Mar 6, 2025 08:30AM Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11

Jan 10, 2025 08:04AM Barinthus Biotherapeutics (BRNS) Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

Nov 25, 2024 04:01PM Barinthus Biotherapeutics (BRNS) Appoints Geoffrey Lynn to Chief Scientific Officer

Nov 19, 2024 06:59AM H.C. Wainwright Reiterates Buy Rating on Barinthus Biotherapeutics (BRNS)

Nov 15, 2024 11:05AM Barinthus Biotherapeutics (BRNS) Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial

Nov 15, 2024 11:01AM Arbutus Biopharma (ABUS) and Barinthus Bio (BRNS) Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Oct 2, 2024 06:46AM H.C. Wainwright Reiterates Buy Rating on Barinthus Biotherapeutics (BRNS)

Oct 1, 2024 08:03AM Barinthus Biotherapeutics (BRNS) Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer

Sep 26, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on Barinthus Biotherapeutics (BRNS)

Sep 24, 2024 08:03AM Barinthus Biotherapeutics (BRNS) Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Aug 8, 2024 09:24AM Barinthus Biotherapeutics plc (BRNS) Misses Q2 EPS by 3c

Jun 14, 2024 06:35AM Barinthus Biotherapeutics (BRNS) PT Lowered to $5 at H.C. Wainwright

Jun 12, 2024 04:01PM Barinthus Biotherapeutics (BRNS) Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections